Archive for the ‘Biotechnology’ Category


Wednesday, February 16th, 2011

Energy Indaba 2011 has concluded an agreement with the EU African Caribbean and Pacific Group of States (ACP) Science and Technology Programme to hold a workshop on Sustainable Non-Food Sources of Bio-Fuels alongside this year’s conference and exhibition to be held in March.

The EU ACP Programme has initiated a Science and Technology project to build sustainable, non-food, renewable biofuel supply chains for providing Combined Heat and Power (CHP), or cogeneration electricity, and identify future feed stocks needed to replace fossil fuels in South Africa, Namibia and Ghana.

The programme aims to bring together academics, professionals, decision-makers and support scheme managers from these African countries and Italy and the UK in a series of workshops to build capacity and identify and stimulate funding for the biofuels industry.

Our Government’s commitment to renewable energy has facilitated several opportunities for the biofuels market in South Africa, giving the ACP
programme and interested stakeholders a strong platform for furthering developments in this industry
,” says Energy Indaba MD, Liz Hart.

The workshop will host a number of local and international industry and research experts in the field of renewable energy and non-food energy sources. The workshop will go further in identifying viable and sustainable renewable energy sources and establishing training programmes in South Africa, to provide a framework for what the organisers hope will accommodate many future projects and programmes in the growing biofuels industry in South Africa.

Non-food biofuels include those based on jatropha plants, which thrive in the African environment, as well as micro-algae and bio-gas from agro-and food wastes. ACP hopes to foster partnerships between energy businesses and farming supply chains, transferring know-how from experienced teams toothers and providing capacity-building for the ACP programme at universities that will train up a new workforce and offer technical expertise, training and research.

“One of the objectives of the programme is to address ACP in-country state-of-preparedness and the ability to respond to new technologies emerging from Europe,” says Professor Patricia Harvey. “Energy Indabais the ideal forum to raise awareness of second-generation renewable biofuels for meeting energy requirements in local communities, and to expand the renewable biofuels debate in Africa.”

For more information visit or contact

As power prices in Africa rise, grid expansion stalls and as grid power availability is constrained, consumers and communities increasingly have to take electricity production into their own hands. In the long term, this is a good thing, and having a portion of electricity coming from decentralised sources is healthy for any grid.

Adapting to a New Reality: The Impact of the Health Care Reform on Medical Device Manufacturing

Wednesday, November 10th, 2010

Thomas Novelli, the Chairman of the marcus evans Medical Device Manufacturing Summit Fall 2010, talks about improving efficiency and preparing for upcoming changes in the industry.

Interview with: Thomas Novelli, Vice President of Government Affairs, Medical Device Manufacturers Association

Hollywood, FL, September 16, 2010 – FOR IMMEDIATE RELEASE

The medical device manufacturing industry needs to find ways of cutting costs and minimizing the impact of future excise taxes that the Health Care Reform will bring about, advises Thomas Novelli, Vice President of Government Affairs at the Medical Device Manufacturers Association. The Chairman of the marcus evans Medical Device Manufacturing Summit Fall 2010 taking place in Hollywood, Florida, December 5-7, Novelli discusses the need for cost cutting and where the opportunities for leaner production may lie.

What are some of the upcoming changes that medical device manufacturers should be prepared for?

Thomas Novelli: In the next few years, medical device manufacturing executives will have to adapt to the changes made in the new healthcare laws. One issue that will directly impact them is the 2.3 percent excise tax, therefore they will need to find ways to minimize this effect.

Looking forward, executives have to find much leaner production methods, cutting costs where possible. For example, they can look at their supply chain management systems. They should be finding more efficient approaches, minimizing distribution delays and executing high-quality manufacturing practices, such as six-sigma.

What long-term strategies would you suggest?

Thomas Novelli: In supply chain management systems, mid-sized companies are not as efficient as they could be. It is essential for them to look at the best practices in the industry – this could be industry leaders, or small companies like themselves. By looking at these practices, they can learn what they need to do to improve their Just-in-Time strategies and make sure that the product lifecycle process is being implemented and utilized to its fullest potential.

Medical device manufacturers should also be aware of new disclosure requirements. The law provisions require device manufacturers to disclose the payments that they make. In addition, they need to be prepared for the research division of the litigation, as a private public entity called The Patient’s Centre of Malcolm’s Research Institute will start to guide pairs within the healthcare system, such as Medicare and Medicate, and provide them with evidence on medical interventions, drugs, devices, and more. My advice is: target equipment gain, as technology is always moving forward, and the appropriate evidence is going to help you not only secure regulatory purpose problems, but reimbursement as well.

How can innovation in medical device manufacturing be enhanced?

Thomas Novelli: In order for innovation to take place, there has to be a favorable environment. The medical device industry is different from the pharmaceutical industry, in the sense that most of the innovation takes place in small or mid-sized companies. These smaller companies are developing innovative technologies and commercializing them themselves, or being acquired by larger corporations.

To have a favorable regulatory and legislative environment, there must be a clearly proven medical technology. In recent years, the Food and Drug Administration (FDA) has become less predictable and timely for device application approval with the agency. This has led to a back-up of applications and venture capitalists who have invested in these companies and are choosing to stop due to problems they are seeing in the FDA. In order for investors to continue to invest and promote innovation, this situation must be resolved.

Contact: Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division

About the Medical Device Manufacturing Summit Fall 2010

This unique forum will take place at The Westin Diplomat Resort & Spa, Hollywood, Florida, December 5-7, 2010. Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The summit includes presentations on lean manufacturing, supply chain and risk management, and staying ahead of FDA regulations.

For more information please send an email to Jana Urbanovska at or visit the event website at

Please note that the summit is a closed business event and the number of participants strictly limited.

About marcus evans Summits

marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings. For more information, please visit

All rights reserved. The above content may be republished or reproduced – kindly inform us by sending an email to

BioNetworks East 2010 special 25% Discount for GTM Subscribers

Tuesday, January 12th, 2010




Special Going to Meet Discount: Register now and receive 25% off (save up to $800)

Register online or call 646-200-7530. Mention Booking Code: 10840.004XZ587.


March 15-17, 2010
Eden Roc, A Renaissance Resort and Spa
Miami Beach, FL

The following speakers are already committed to attending Bionetwork East:

  • David H. Donabedian, PhD, MBA, Vice President, Strategic Alliances, US CEEDD, GSK
  • Laura Pierce, Vice President, Alliance Management, Bayer HealthCare Pharmaceuticals
  • Carlos Garrido, Finance Director , Head of Strategic Planning and Business Development South America, AstraZeneca
  • Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune
  • Michael Lytton, EVP Business Development, Biogen Idec Inc
  • Graham Brazier, VP, Therapeutic and Commercial Transactions, BMS
  • Michael Leonetti; Head, Health Care Partnerships, Boehringer Ingelheim
  • Mark A. Miller, Vice President of Corporate Business Development, Eli Lilly
  • Adelene Perkins, President and Chief Business Officer, Infinity Pharmaceuticals
  • Reid Leonard, Vice President External Licensing and Business Development,Merck
  • Jules Musling, VP, Johnson & Johnson
  • Jennifer Tegfeldt, Director Business Initiatives & Strategies, Genzyme

View the full speaker list

Access the agenda

Year on year, your colleagues – the thought leaders and key decision makers in the Pharma space – come together at BioNetwork to meet with their peers in a casual setting and discuss the substantive issues impacting your industry.

You asked and we listened: This year’s BioNetwork will feature a host of new networking formats. Check out our website soon for more information.

Improved one-to-one partnering software and onsite facebook!Networking is made easier than ever before, thus facilitating tactical relationships between speakers and attendees.

If you are not serious about strategic growth through partnerships, this is not the event for you. However, if you are a senior-level decision maker who is committed to growth through meaningful partnerships you cannot afford to miss this event.

More networking opportunities, more case studies, and more senior-level executive participation – BioNetwork East is the must partnering event for spring 2010.

Register by 1/29 with booking code 10840.004XZ587 to get 25% off the final pricing tier.

3 Easy Ways to Register
Call Carly Smiga at 646.200.7530


Sponsored By:


Sponsorship opportunities always sell out. For sponsorship and speaking opportunities contact Ariel Borkowsky at or call 646-200-7476.

  • All discounts are taken off the full conference price. No two discounts or offers can be combined.
  • Payment is due in full at the time of registration. Your registration will not be confirmed until payment is received and may be subject to cancellation.
  • Discount cannot be applied to previously booked registrations.


To view this email as a web page, go here.

This email was sent to: .
This email was sent by: Worldwide Business Research
535 Fifth Ave, 8th Floor New York, New York, 10017 USA

Go here to leave this mailing list or modify your email profile. 
We respect your right to privacy. View our policy.

Worldwide Business Research (WBR) is the leading producer of world-wide, annual, large-scale executive level conferences. Through extensive market research, WBR’s highly focused events deliver timely, need-to-know information. Through carefully crafted, powerful case study presentations you will learn how leaders in your industry have tackled the same significant issues that you face on a daily basis.